Scandinavian journal of gastroenterology
Cure8 research brief
Why This Matters
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis on biologic therapy, clinicians who manage IBD, and researchers studying non-invasive disease monitoring.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This was a one-year prospective observational study of 77 adults with Crohn's disease or ulcerative colitis, many receiving infliximab. IUS-defined transmural remission (bowel wall thickness ≤3 mm and no Doppler signal) and endoscopic remission were both associated with higher 1-year treatment persistence.
Rates of persistence and mean days on therapy were similar when comparing IUS and endoscopy, and patients who met both TR and ER had especially high persistence.
Study limits and practical points The report is an abstract-level summary from a single cohort; details such as exact inclusion criteria, statistical adjustments, and longer-term outcomes are not provided here. IUS requires trained operators and standardized definitions to be most useful.
Discuss with your care team whether IUS is available and appropriate for monitoring treatment response in your situation.
Keep In Mind
This entry is based on an abstract-level journal summary of a single prospective cohort (n=77). The findings are promising but should be interpreted in the context of study size, operator-dependence of IUS, and lack of full-methods detail in the abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationScandinavian journal of gastroenterology
AuthorsJohan F K F Ilvemark, Katrine R Christensen, Casper Steenholdt +5 more
InstitutionDepartment of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 11, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dose escalation for secondary loss of response in inflammatory bowel disease: 3-year outcomes and treatment persistence.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.